Tanno Luciana Kase, Demoly Pascal, Martin Bryan, Berstein Jonathan, Morais-Almeida Mario, Levin Michael, Fiocchi Alessandro, Sánchez-Borges Mario, Caraballo Luis R, Wong Gary, Ortega-Martell José Antonio, Rouadi Philip, Yáñez Anahí, Wang Liang Lu, Peden David B, Chikhladze Manana, González-Díaz Sandra N, Fontaine Jean-François, Sublett James, Chang Yoon-Seok, Passalacqua Giovanni, Ansotegui Ignacio J, Ebisawa Motohiro, Senna Gianenrico, Caminati Marco
Hospital Sírio-Libanês, Brazil.
University Hospital of Montpellier, Montpellier, France.
World Allergy Organ J. 2021 Feb;14(2):100515. doi: 10.1016/j.waojou.2021.100515. Epub 2021 Jan 31.
The COVID-19 outbreak brought an unprecedented challenge to the world. Knowledge in the field has been increasing exponentially and the main allergy societies have produced guidance documents for better management of allergic patients during this period. However, few publications so far have provided real-life data from the allergy community concerning allergy practice during the COVID-19 outbreak. Therefore, we proposed an international survey on the management of allergic patients during the current pandemic.
We performed an online survey undertaken to reach out the worldwide allergy community by e-mail and social media. The web-based questionnaire contained 24 questions covering demographic data from the participants, clinical practice during this period, and questions related to the new international classification and coding tools addressed for COVID-19. It was circulated for 8 weeks and had anonymous and volunteer context.
Data are presented for 635 participants from 78 countries of all continents. Allergists with long-term professional experience were the main audience. As expected, we received many responses as "I have no data" or "I don't know" to the questions of the survey. However, most with more experience on managing allergic patients during the pandemic agreed that patients suffering from allergic or hypersensitivity conditions have no increased risk of contracting COVID-19 or developing SARS CoV-2. Also, participants mentioned that none of the allergy treatments (inhaled corticosteroids, allergen immunotherapy, biological agents) increased the risk of contracting COVID-19 infection including severe presentations.
The data presented are a starting point in the process of getting feedback on all the recommendations provided by the allergy societies; it could also be the basis of new strategies to support health professionals while new COVID-19 specific treatments and vaccines are being explored. The information here presented intends to be helpful to the community but represents a course of action in a highly specific situation due to the state of emergency, and it should be helpful to health systems.
新冠疫情给全球带来了前所未有的挑战。该领域的知识呈指数级增长,主要过敏学会已制定指导文件,以便在此期间更好地管理过敏患者。然而,迄今为止,很少有出版物提供过敏领域在新冠疫情期间过敏诊疗的实际数据。因此,我们发起了一项关于当前疫情期间过敏患者管理的国际调查。
我们通过电子邮件和社交媒体进行了一项在线调查,以覆盖全球过敏领域。基于网络的问卷包含24个问题,涵盖参与者的人口统计学数据、在此期间的临床实践,以及与新冠疫情相关的新国际分类和编码工具的问题。该问卷共发放8周,采用匿名和自愿参与的方式。
来自各大洲78个国家的635名参与者提供了数据。主要受众是具有长期专业经验的过敏症专科医生。不出所料,对于调查中的问题,我们收到了许多“我没有数据”或“我不知道”的回复。然而,大多数在疫情期间管理过敏患者经验更丰富的人一致认为,患有过敏或超敏反应疾病的患者感染新冠病毒或感染严重急性呼吸综合征冠状病毒2的风险并未增加。此外,参与者提到,没有一种过敏治疗方法(吸入性糖皮质激素、变应原免疫疗法、生物制剂)会增加感染新冠病毒包括重症的风险。
所呈现的数据是获取过敏学会提供的所有建议反馈过程的起点;它也可能是在探索新冠病毒特异性新治疗方法和疫苗时支持卫生专业人员的新策略的基础。这里呈现的信息旨在对该领域有所帮助,但由于紧急状态,它代表了在高度特定情况下的一种行动方案,应该会对卫生系统有所帮助。